This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and industrials editor/analyst Isaac Pino discuss topics across the investing world.

Continuing our Motley Fool Madness series, Isaac and David go head-to-head analyzing Pfizer and Alcoa. In this showdown, Alcoa enters as the No. 12 seed, as the company's stock outperformed the majority of its Dow peers over the past three years. Despite Pfizer's troubles with the patent cliff, the big pharma heavyweight is still a formidable opponent with an attractive dividend.

While Isaac and David present strong arguments for both companies, a team of all-star Motley Fool analysts will ultimately select who advances in the Dow bracket.

Investors looking for solid American stocks that are expanding their global footprint should look no further than The Motley Fool's recent special free report, "3 Companies Set to Dominate the World." The report is free today but won't be forever, so check out your copy today by clicking here. Enjoy, and Fool on!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.